PE20151206A1 - Polipeptidos del factor vii de accion corta - Google Patents

Polipeptidos del factor vii de accion corta

Info

Publication number
PE20151206A1
PE20151206A1 PE2015001020A PE2015001020A PE20151206A1 PE 20151206 A1 PE20151206 A1 PE 20151206A1 PE 2015001020 A PE2015001020 A PE 2015001020A PE 2015001020 A PE2015001020 A PE 2015001020A PE 20151206 A1 PE20151206 A1 PE 20151206A1
Authority
PE
Peru
Prior art keywords
polypeptides
factor vii
action factor
short action
treatment
Prior art date
Application number
PE2015001020A
Other languages
English (en)
Inventor
Maxine Bauzon
Terry Hermiston
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51022016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151206(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PE20151206A1 publication Critical patent/PE20151206A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Referidas a peptidos del factor Vll de accion corta. Una vida media acortada es deseable para el tratamiento de hemorragia aguda y trastornos similares. La modificacion de la sializacion y/o de la glucosilacion del factor Vll y de variantes del mismo produce peptidos utiles en el tratamiento de afecciones de hemorragia aguda
PE2015001020A 2012-12-24 2013-12-23 Polipeptidos del factor vii de accion corta PE20151206A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745674P 2012-12-24 2012-12-24
US201361787026P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PE20151206A1 true PE20151206A1 (es) 2015-09-04

Family

ID=51022016

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015001020A PE20151206A1 (es) 2012-12-24 2013-12-23 Polipeptidos del factor vii de accion corta
PE2020001539A PE20211303A1 (es) 2012-12-24 2013-12-23 Polipeptidos del factor vii de accion corta

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2020001539A PE20211303A1 (es) 2012-12-24 2013-12-23 Polipeptidos del factor vii de accion corta

Country Status (21)

Country Link
US (5) US20150344863A1 (es)
EP (3) EP2938351B8 (es)
JP (3) JP6566869B2 (es)
KR (2) KR102047235B1 (es)
CN (2) CN107099522A (es)
AU (2) AU2013370522B2 (es)
BR (1) BR112015015182B1 (es)
CA (2) CA3185756A1 (es)
DK (3) DK3572090T3 (es)
ES (3) ES2936485T3 (es)
HK (1) HK1216855A1 (es)
IL (2) IL239345B (es)
MX (2) MX2015007712A (es)
NZ (1) NZ708873A (es)
PE (2) PE20151206A1 (es)
PL (3) PL3165232T3 (es)
SA (1) SA517380867B1 (es)
SG (2) SG10201710593UA (es)
TW (3) TWI681968B (es)
WO (1) WO2014105784A1 (es)
ZA (1) ZA201505315B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150344863A1 (en) 2012-12-24 2015-12-03 Bayer Healthcare Llc Short-acting factor vii polypeptides
TW201629215A (zh) * 2014-09-30 2016-08-16 拜耳保健有限責任公司 使用凝血酶之組成物及治療方法
KR101755838B1 (ko) 2015-09-09 2017-07-07 현대자동차주식회사 엔진 예열장치 및 그 예열방법
MX2019002734A (es) * 2016-09-13 2019-05-27 Bayer Healthcare Llc Glicoformas del factor viia.
KR102120921B1 (ko) * 2017-02-10 2020-06-10 주식회사 일리아스바이오로직스 Gba 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 고셔병 예방 및 치료용 약학적 조성물
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3008252A (en) 1959-02-02 1961-11-14 Beatrice V Robinson Puffed sleeve ironer
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
FR2632524B1 (fr) 1988-06-09 1992-03-13 Fondation Nale Transfusion San Procede de preparation d'une fraction concentree en facteur viia et son application a titre de medicament
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP1299126B1 (en) 2000-05-23 2004-10-27 Neurologix, Inc. Glutamic acid decarboxylase (gad) delivery system for treating neurodegenerative diseases
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US20050221335A1 (en) 2001-12-14 2005-10-06 Anthony Kavanagh Reporter gene
SI1499719T1 (sl) * 2002-04-30 2011-03-31 Bayer Healthcare Llc Polipeptidne variante faktorja VII ali VIIa
US8512710B2 (en) 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
WO2004083361A2 (en) * 2003-03-20 2004-09-30 Maxygen Holdings Ltd. FVII OR FVIIa VARIANTS
CA2529828C (en) * 2003-06-19 2013-01-15 Maxygen Holdings Ltd. Factor vii or viia gla domain variants
US20060198819A1 (en) * 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
CN101870729A (zh) * 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
CN103627670B (zh) 2004-02-13 2016-12-21 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
WO2005108568A1 (en) 2004-05-10 2005-11-17 Basf Plant Science Gmbh Methods for assembling multiple expression constructs
EP1761630A2 (en) 2004-06-21 2007-03-14 Novo Nordisk Health Care AG Glycosylation-disrupted factor vii variants
EP1861124A2 (en) 2005-03-11 2007-12-05 Fresenius Kabi Deutschland GmbH Production of bioactive glycoproteins from inactive starting materials by conjugation with hydroxyalkylstarch
US20080188400A1 (en) * 2005-04-26 2008-08-07 Maxygen Holdings Ltd. Methods For Treating Bleeding
PT1907540E (pt) * 2005-07-22 2013-02-04 Bayer Healthcare Llc Activação do factor vii em solução
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
AU2006280932A1 (en) * 2005-08-19 2007-02-22 Novo Nordisk A/S Glycopegylated factor VII and factor Vila
CA2628848A1 (en) * 2005-11-08 2007-05-18 Astellas Pharma Inc. Compositions and methods for treating thrombocytopenia
TW200813017A (en) * 2006-05-05 2008-03-16 Millennium Pharm Inc Factor XA inhibitors
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
US7532621B2 (en) 2006-08-30 2009-05-12 Cornell Research Foundation, Inc. Lateral error correction for time-critical multicast
US20100026939A1 (en) 2006-12-20 2010-02-04 Sumitomo Chemical Company, Limited Polarizer and liquid crystal display device
CA2674239C (en) * 2006-12-28 2018-01-23 Centocor Ortho Biotech Inc. Methods and vectors for generating asialylated immunoglobulins
ES2492469T3 (es) * 2007-02-20 2014-09-09 Dsm Ip Assets B.V. Nueva sialidasa
JP6050927B2 (ja) 2007-04-26 2016-12-21 シーエヌジェイ ホールディングス，インコーポレイテッド 高シアル酸含量を有する組換えビタミンｋ依存性タンパク質およびその調製方法
CA2702120C (en) 2007-10-12 2016-05-17 Sigma Aldrich Co. Compositions and methods for improved glycoprotein sialylation
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP2987498B1 (en) * 2008-05-02 2017-07-05 Laboratoire Français du Fractionnement et des Biotechnologies Treatment of bleeding with low half-life fibrinogen
JP2010022253A (ja) * 2008-07-17 2010-02-04 Kaneka Corp アシアロ糖鎖化合物の作製方法
CA2776949A1 (en) 2008-12-05 2010-06-10 The Regents Of The University Of California Methods and compositions for treating p.acnes
US8400974B2 (en) * 2009-07-30 2013-03-19 Apple Inc. Methods and apparatus for providing dynamic information in a wireless information channel
US20130196410A1 (en) 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
WO2013017555A1 (en) * 2011-08-01 2013-02-07 Lfb-Biotechnologies Factor vii compositions with specific glycosylation for controlled half-life
US20150344863A1 (en) 2012-12-24 2015-12-03 Bayer Healthcare Llc Short-acting factor vii polypeptides

Also Published As

Publication number Publication date
CN105025913A (zh) 2015-11-04
AU2013370522A2 (en) 2016-10-06
KR20150127573A (ko) 2015-11-17
KR102111934B1 (ko) 2020-05-18
EP2938351A1 (en) 2015-11-04
JP2017071608A (ja) 2017-04-13
AU2013370522A1 (en) 2015-07-09
US20160376578A1 (en) 2016-12-29
TWI708783B (zh) 2020-11-01
US20150344863A1 (en) 2015-12-03
EP2938351B8 (en) 2019-07-31
NZ708873A (en) 2019-11-29
IL239345A0 (en) 2015-07-30
SA517380867B1 (ar) 2020-06-10
DK3572090T3 (da) 2023-01-09
ES2747726T3 (es) 2020-03-11
PE20211303A1 (es) 2021-07-20
DK2938351T3 (da) 2019-09-23
MX2015007712A (es) 2015-09-07
EP3165232A1 (en) 2017-05-10
TWI743542B (zh) 2021-10-21
WO2014105784A1 (en) 2014-07-03
AU2013370522B2 (en) 2019-01-17
IL273559A (en) 2020-05-31
AU2019202663A1 (en) 2019-05-09
BR112015015182B1 (pt) 2023-12-26
US10273466B2 (en) 2019-04-30
US20140363419A1 (en) 2014-12-11
ES2746116T3 (es) 2020-03-04
HK1216855A1 (zh) 2016-12-09
ZA201505315B (en) 2022-11-30
EP2938351B1 (en) 2019-06-26
AU2019202663B2 (en) 2020-09-10
CA3185756A1 (en) 2014-07-03
EP2938351A4 (en) 2016-08-24
EP3572090A1 (en) 2019-11-27
CA2896057C (en) 2023-03-14
SG11201504986QA (en) 2015-07-30
TW201920254A (zh) 2019-06-01
DK3165232T3 (da) 2019-09-16
NZ749488A (en) 2021-09-24
CN107099522A (zh) 2017-08-29
ES2936485T3 (es) 2023-03-17
SG10201710593UA (en) 2018-02-27
PL2938351T3 (pl) 2020-03-31
JP2016507506A (ja) 2016-03-10
EP3165232B1 (en) 2019-07-10
PL3165232T3 (pl) 2019-12-31
US20210002624A1 (en) 2021-01-07
CA2896057A1 (en) 2014-07-03
PL3572090T3 (pl) 2023-04-11
TW201431876A (zh) 2014-08-16
TWI681968B (zh) 2020-01-11
JP6363677B2 (ja) 2018-07-25
IL239345B (en) 2020-04-30
EP3572090B1 (en) 2022-12-14
US10717970B2 (en) 2020-07-21
KR102047235B1 (ko) 2019-11-22
JP6566869B2 (ja) 2019-08-28
BR112015015182A2 (pt) 2019-07-30
MX2021002985A (es) 2021-05-14
US20230295596A1 (en) 2023-09-21
JP2019213540A (ja) 2019-12-19
IL273559B (en) 2022-04-01
US11530401B2 (en) 2022-12-20
KR20190072686A (ko) 2019-06-25
TW202026309A (zh) 2020-07-16

Similar Documents

Publication Publication Date Title
PE20151206A1 (es) Polipeptidos del factor vii de accion corta
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
AR095977A1 (es) Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
UY35731A (es) Éteres de arilo y sus usos
EA201692105A1 (ru) Новые пиразолопиримидиновые производные и их применение в качестве ингибиторов malt1
NI201500117A (es) Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos.
UY34192A (es) ?proceso para reducir pez en medio acuoso; carbonato de calcio molido y/o precipitado hidrofobizado; y uso y compuesto del mismo?.
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
MX2020003096A (es) Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
BR112013028187A2 (pt) processo para produzir olefinas
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
EA201791424A1 (ru) Получение белка
HK1260897A1 (zh) 使用四氫異喹啉小分子來結合並調節pcsk9的蛋白活性的組合物和方法
CO6870047A2 (es) Soporte basado en fibras celulósicas y/o sintéticas, método para producirlo y uso del soporte
UY34268A (es) Métodos para aumentar el contenido de proteínas,aceites y/o aminoácidos en una planta
BR112014021326A2 (pt) célula para a expressão de protéina, método para reduzir a atividade de amidação de peptídeo em uma determinada célula, uso de uma célula
TR201819270T4 (tr) Glikozaminoglikanlar Ve Siklodekstrinlerin Kombinasyonu
AU351343S (en) Headgear
UY34267A (es) Métodos para aumentar el contenido de proteínas,aceites y/o aminoácidos en una planta
ES2586805T3 (es) Análogos de péptidos para tratar enfermedades y trastornos
CY1119212T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
AR095890A1 (es) Uso de ácido trifluoroacético y sales del mismo para tratar la hipercolesterolemia
UY34266A (es) Métodos para aumentar el contenido de proteínas,aceites y/o aminoácidos en una planta